[Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines].

about

Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo

P2860

Q36710252-5DD7A846-B7D6-4F49-882F-0219CCF8D446

P2860

[Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines].

Item

http://www.wikidata.org/entity/Q55465317

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@en

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@nl

type

Item

label

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@en

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@nl

prefLabel

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@en

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@nl

P1476

[Effects of monoclonal antibod ...... cell lung cancer cell lines].

@en

P2093

Zhen Chen

http://www.w3.org/2001/XMLSchema#string

Zhiwei Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy.

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.

The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

P304

769-772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2010.08.03

http://www.w3.org/2001/XMLSchema#string

P407

Chinese

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20704815

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

P932

6000554

http://www.w3.org/2001/XMLSchema#string

[Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines].

about

P2860

P2860

[Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932